Physician profile
Michael E Neuland
NPI 1467442525
$21,758.79
in general payments reported to CMS, 2019-2025
40 companies · $3,817 in 2025
The $3,817 reported for 2025 was more than what 80% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,173 · 2020: $2,176 · 2021: $3,471 · 2022: $3,487 · 2023: $3,050 · 2024: $3,585 · 2025: $3,817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $287 · Consulting Fee: $24.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,140.72 |
| Education | $287.00 |
| Consulting Fee | $24.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,926.75 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $3,177.85 | 2019-2025 | Trelegy Ellipta, Nucala |
| Regeneron Healthcare Solutions, INC. | $2,321.67 | 2019-2025 | Dupixent |
| Genzyme Corporation | $2,252.96 | 2019-2025 | |
| Csl Behring | $1,867.06 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Grifols USA, LLC | $1,369.57 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Pharming Healthcare, INC. | $918.71 | 2019-2025 | Ruconest |
| Amgen INC. | $811.71 | 2021-2025 | Tezspire, Actimmune |
| Genentech USA, INC. | $638.05 | 2019-2025 | Xolair |
| Octapharma USA, INC. | $593.89 | 2020-2024 | Cutaquig |
| Takeda Pharmaceuticals U.S.A., INC. | $501.02 | 2021-2025 | Cuvitru, Takhzyro, Hyqvia |
| Insmed, INC. | $420.17 | 2024-2025 | Arikayce, Brinsupri |
| Pfizer INC. | $384.73 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $359.98 | 2021-2025 | Orladeyo |
| Kaleo, INC. | $319.94 | 2019-2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Neuland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.